Page 27 - 51 the significance--29.2_opt

56. Dabelea D, Snell-Bergeon JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS.
Increasing prevalence of gestational diabetes mellitus (GDM) over time and by
birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes
care 2005;28(3):579-84.
57. Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ,
et al. Increased incidence of gestational diabetes in women receiving prophylactic
17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
Diabetes care 2007;30(9):2277-80.
58. Pinney SE, Simmons RA. Epigenetic mechanisms in the development of type 2
diabetes. Trends Endocrinol Metab 2010;21(4):223-9.
59. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk
for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary
syndrome: a prospective, controlled study in 254 affected women. The Journal of
clinical endocrinology and metabolism 1999;84(1):165-9.
60. Fowler M. Macrovascular and microvascular complications in type 2 diabetes
patients. Clinical Diabetes 2008;26(2):77-82.
61. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.
Diabetes 2005;54(6):1615-25.
62. Gerich JE. Clinical significance, pathogenesis, and management of postprandial
hyperglycemia. Archives of internal medicine 2003;163(11):1306-16.
63. Brownlee M. Biochemistry and molecular cell biology of diabetic complications.
Nature 2001;414(6865):813-20.
64. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retino-
pathy in diabetes. Diabetes care 2004;27 Suppl 1:S84-7.
65. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. The Medical
clinics of North America 2004;88(4):1001-36, xi.
66. Koro CE, et al. Antidiabetic medication use and prevalence of chronic kidney
disease among patients with type 2 diabetes mellitus in the United States. Clin.
Therapeutics 2009;31(11):2608-17.
67. ADA. Standards of medical care in diabetes--2009. Diabetes care 2009;32 Suppl 1:
S13-61.
68. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia
2000;43(8):957-73.
69. Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A, et al. The
prevalence of peripheral neuropathy in a population-based study of patients with
type 2 diabetes in Sweden. Journal of diabetes and its complications 2010.
70. Lauterbach S, Kostev K, Becker R. Characteristics of diabetic patients visiting a
podiatry practice in Germany. J Wound Care 2010;19(4):140-44.
71. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of
diabetic peripheral neuropathy in the US. Diabetes care 2003;26(6):1790-5.
72. International Diabetes Federation. Time to Act: Diabetes and Foot Care: Interna-
tional Diabetes Federation, 2005.
73. Apelqvist J, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with
foot ulcers. Journal of internal medicine 1993;233(6):485-91.
74. Faglia E, Favales F, Morabito A. New ulceration, new major amputation, and
survival rates in diabetic subjects hospitalized for foot ulceration from 1990 to 1993:
a 6.5-year follow-up. Diabetes care 2001;24(1):78-83.
75. Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the outcome of the
management of diabetic foot ulcers using ulcer-related and person-related measures.
Diabetes care 2006;29(8):1784-7.
76. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot
ulcers stratified by etiology. Diabetes care 2003;26(2):491-4.
77. Naschitz JE, Lenger R. Why traumatic leg amputees are at increased risk for cardio
vascular diseases. QJM 2008;101(4):251-9.
78. Resnick HE, Carter EA, Lindsay R, Henly SJ, Ness FK, Welty TK, et al. Relation of lower-
extremity amputation to all-cause and cardiovascular disease mortality in American
Indians: the Strong Heart Study. Diabetes care 2004;27(6):1286-93.
79. Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP. Mortality
and hospitalization in patients after amputation: a comparison between patients
with and without diabetes. Diabetes care 2006;29(10):2252-6.
80. Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, et al.
Resource utilisation and costs associated with the treatment of diabetic foot ulcers.
Prospective data from the Eurodiale Study. Diabetologia 2008;51(10):1826-34.

27